Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.